EG 427 Receives U.S. FDA Fast Track Designation for EG110A DNA Medicine in Neurogenic Bladder Patients
October 06, 2025- Builds on positive top-line data from first cohort demonstrationg significant reduction in urinary incontinence episodes
Read the Press Release here
Recent posts
EG 427 Announces Compelling Initial Topline Clinical Results with EG110A DNA Medicine in Neurogenic Bladder Patients
EG 427 highlights at ASGCT major advances made with its HERMES platform in neurology using versatile non-replicative herpes vectors
Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladder
